Dr. Khalil Al Farsi describes a CLL patient case study providing insights on the background and treatment approach.
Dr. Khalil Al Farsi, Oman
Edit Video Component
Dr. Khalil Al Farsi, Senior consultant, Haematology and BMT, Sultan Qaboos University Hospital, Muscat, Oman discuses about Guideline updates and its use in the real-world experience with CLL case presentation.
• Explains a patient case with background and treatment approach
• Clinical evidence of acalabrutinib over CLL from ELEVATE-TN trial data.
• Prolymphocytic Leukemia (PLL) from surveillance epidemiology and end results (SEER) based study from 1998 to 2016.
• Other research studies conducted with drugs and its combination on B cell and T-cell prolymphocytic Leukemia.
Explore more videos
Configure Image Component
2nd GCC Haematology Forum- CLL Case Discussion Focus on Safety Profile of BTKi
Dr. Ruba Taha, Qatar
Configure Image Component
Expert Guidance for the Treatment of CLL
Dr. Susan M. O'Brien, US
Configure Image Component
Panel discussion
Dr. Ayman Al Hejazi, KSA
Modal Window Component Section Begins
Modal Window Component Section Ends